Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vaccines Shakeup Continues In China: NT Pharma Backs Away From GSK

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's largest vaccine distributor China NT Pharma Group announced Aug. 17 it will not renew its master distribution contract with its largest customer GlaxoSmithKline PLC, in part, it appears, due to burdens created by the new China Pharmacopeia that was issued at the end of 2010
Advertisement

Related Content

China’s Best Shot: GSK, Novartis Gear Up For Vaccine Prime Time
Merck Ties Up With Zhifei To Distribute Gardasil In China, But What Happened To Sinopharm?
Merck Ties Up With Zhifei To Distribute Gardasil In China, But What Happened To Sinopharm?
Hepatitis A Vaccinations On The Rise In Asia With Travelers From Developed Nations Most At Risk
Beijing's SL Pharma and Canada's PnuVax Form Vaccine, Antibody JV
China's Largest Pharma Promoter CMS Outpaced Market With Unique Specialty Pharma Focus
WuXi Celebrates First $100 Million Quarter; Sinovac Reports 50% Revenue Increase; SciClone Not Worried About Zydaxin Cuts: China Earnings Round Up (Part 1)
With Limits Created By China's New Pharmacopoeia, What's Next For Vaccine Manufacturers?
With Limits Created By China's New Pharmacopoeia, What's Next For Vaccine Manufacturers?
GSK Buys Out Neptunus Stake in Chinese Vaccines JV; Are New Pharmacopoeia Standards At Play?
Advertisement
UsernamePublicRestriction

Register

SC078855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel